Provided by Tiger Trade Technology Pte. Ltd.

Clearmind Medicine, Inc.

0.7150
-0.0008-0.11%
Post-market: 0.73000.0150+2.10%17:05 EDT
Volume:95.87K
Turnover:69.36K
Market Cap:2.41M
PE:-0.05
High:0.7400
Open:0.7400
Low:0.7055
Close:0.7158
52wk High:480.00
52wk Low:0.7055
Shares:3.37M
Float Shares:3.37M
Volume Ratio:0.94
T/O Rate:2.85%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-14.8013
EPS(LYR):-303.4772
ROE:-106.98%
ROA:-53.08%
PB:0.19
PE(LYR):0.00

Loading ...

Clearmind Medicine completes Part A of CMND-100 trial

TIPRANKS
·
Jul 28

Clearmind Medicine Successfully Completes Part a of Its FDA Regulated Phase I/Ii Trial

Reuters
·
Jul 28

Clearmind Completes Part a Dosing in Phase I/II Cmnd-100 Trial for Alcohol Use Disorder

Reuters
·
Jul 28

Clearmind Targets Hong Kong Patent Protection to Support PTSD Drug Development Push

Reuters
·
Jul 20

Clearmind Medicine - Files Hong Kong Patent Application for Psychedelic Compounds Targeting Ptsd

THOMSON REUTERS
·
Jul 20

Clearmind reports positive retention results for intranasal formulation of MEAI

TIPRANKS
·
Jul 16

Clearmind Medicine Releases Update on Intranasal MEAI Formulation Retention Study

Reuters
·
Jul 16

Clearmind Medicine - Results Validate Clearmind Nasal Drug-delivery Platform for Meai

THOMSON REUTERS
·
Jul 16

Clearmind Medicine Reports Positive Retention Results for Intranasal Formulation of Its Psychedelic-based Neuroplastogen Meai

THOMSON REUTERS
·
Jul 16

Clearmind Medicine Posts Update on Cmnd-100 First-in-human Trial Webinar Insights

Reuters
·
Jul 13

Clearmind Medicine submits response to HHS request for information

TIPRANKS
·
Jul 10

Clearmind Medicine Responds to the U.S. Administration’s Rfi for Addiction Treatment Innovations as Part of the Great American Recovery Initiative

THOMSON REUTERS
·
Jul 10

Clearmind Reports Successful Formulation Study for Intranasal MEAI Delivery in Alcohol Use Disorder Program

Reuters
·
Jul 08

Clearmind Medicine Issues Press Release Update

Reuters
·
Jul 07

Clearmind Medicine Wins New US Patent for Binge Behavior Regulators

Reuters
·
Jun 29

Clearmind completes Part A dosing in Phase I/II CMND-100 trial for alcohol use disorder

Reuters
·
Jun 22

Clearmind Medicine - to Initiate Next Stage of Clinical Program for Alcohol Use Disorder

THOMSON REUTERS
·
Jun 22

Clearmind Medicine Reaches Major Milestone, Completing Part a Treatment in FDA‑Regulated Phase I/Ii Trial

THOMSON REUTERS
·
Jun 22

HRT Financial LP disposes of $73,191 in Clearmind Medicine common shares

Reuters
·
Jun 19

Psychedelic: Clearmind completes Part A dosing for Phase I/II CMND-100 trial

TIPRANKS
·
Jun 18